GEN Exclusives

More »

GEN News Highlights

More »
Mar 22, 2007

Eisai Makes a $325M Leap into Biologics Market by Acquiring Morphotek

  • Eisai plans to enter the biologic therapeutics field through a $325-million acquisition of Morphotek.

    The company believes it can hone its focus on addressing unmet medical needs, especially those of cancer patients. Eisai expects to pad its small molecule driven oncology research program with Morphotek's technologies and therapeutic Mabs.

    Eisai plans on closing the transaction sometime during its first fiscal quarter of 2007.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?